Dr. Lindsey Rolfe B.Sc., BSc, MB ChB, MRCP, FFPM Net Worth

The estimated Net Worth of Lindsey Rolfe is at least $782 mil dollars as of 1 November 2022. Dr Rolfe owns over 8,374 units of Clovis Oncology Inc stock worth over $9,284 and over the last 9 years he sold CLVS stock worth over $0. In addition, he makes $773,078 as Exec. VP of Clinical Devel. & Pharmacovigilance and Chief Medical Officer at Clovis Oncology Inc.

Dr FFPM CLVS stock SEC Form 4 insiders trading

Dr has made over 35 trades of the Clovis Oncology Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 8,374 units of CLVS stock worth $670 on 1 November 2022.

The largest trade he's ever made was exercising 23,034 units of Clovis Oncology Inc stock on 6 April 2020 worth over $70,945. On average, Dr trades about 3,764 units every 45 days since 2015. As of 1 November 2022 he still owns at least 116,044 units of Clovis Oncology Inc stock.

You can see the complete history of Dr Rolfe stock trades at the bottom of the page.

Dr. Lindsey Rolfe B.Sc., BSc, MB ChB, MRCP, FFPM biography

Dr. Lindsey Rolfe B.Sc., BSc, MB ChB, MRCP, FFPM is the Exec. VP of Clinical Devel. & Pharmacovigilance and Chief Medical Officer at Clovis Oncology Inc.

What is the salary of Dr FFPM?

As the Exec. VP of Clinical Devel. & Pharmacovigilance and Chief Medical Officer of Clovis Oncology Inc, the total compensation of Dr FFPM at Clovis Oncology Inc is $773,078. There are 1 executives at Clovis Oncology Inc getting paid more, with Patrick J. Mahaffy having the highest compensation of $1,234,574.

How old is Dr FFPM?

Dr FFPM is 53, he's been the Exec. VP of Clinical Devel. & Pharmacovigilance and Chief Medical Officer of Clovis Oncology Inc since . There are 6 older and 1 younger executives at Clovis Oncology Inc. The oldest executive at Clovis Oncology Inc is Dr. Gillian C. Ivers-Read BSc, 67, who is the Co-Founder, Exec. VP & Chief Regulatory Officer.

What's Dr FFPM's mailing address?

Lindsey's mailing address filed with the SEC is C/O ATRECA, INC., 835 INDUSTRIAL RD., SUITE 400, SAN CARLOS, CA, 94070.

Insiders trading at Clovis Oncology Inc

Over the last 13 years, insiders at Clovis Oncology Inc have traded over $37,405,827 worth of Clovis Oncology Inc stock and bought 24,337,722 units worth $298,497,645 . The most active insiders traders include Forest Baskett, Scott D Sandell, ePeter J Barris. On average, Clovis Oncology Inc executives and independent directors trade stock every 17 days with the average trade being worth of $8,863. The most recent stock trade was executed by Paul Edward Gross on 1 November 2022, trading 10,248 units of CLVS stock currently worth $820.

What does Clovis Oncology Inc do?

Complete history of Dr Rolfe stock trades at Clovis Oncology Inc e Atreca Inc

Clovis Oncology Inc executives and stock owners

Clovis Oncology Inc executives and other stock owners filed with the SEC include:

• Patrick J. Mahaffy,
  Co-Founder, CEO, Pres & Exec. Director
• Dr. Lindsey Rolfe B.Sc., BSc, MB ChB, MRCP, FFPM,
  Exec. VP of Clinical Devel. & Pharmacovigilance and Chief Medical Officer
• Patrick J. Mahaffy MA,
  Co-Founder, CEO, Pres & Exec. Director
• Dr. Gillian C. Ivers-Read,
  Co-Founder, Chief Regulatory Officer & Exec. VP of Technical Operations
• Paul Edward Gross,
  Exec. VP, Gen. Counsel & Sec.
• Daniel W. Muehl,
  Exec. VP & CFO
• Dr. Gillian C. Ivers-Read BSc,
  Co-Founder, Exec. VP & Chief Regulatory Officer
• Anna Sussman,
  VP of Investor Relations
• Ann Bozeman,
  Exec. VP of HR
• Breanna Burkart,
  VP of Investor Relations & Corp. Communications
• Dr. Thomas Fuglsang Harding B.Sc., Ph.D.,
  Exec. VP & Chief Scientific Officer
• Keith T. Flaherty,
  Director
• Daniel W Muehl,
  See Remarks
• Lindsey Rolfe,
  See Remarks
• Thorlef Spickschen,
  Director
• Paul H Klingenstein,
  Director
• M James Barrett,
  Director
• Gillian C Ivers Read,
  See Remarks
• Ginger L Graham,
  Director
• Corwin Dale Hooks,
  See Remarks
• Edward J Mc Kinley,
  Director
• Brian G Atwood,
  Director
• Patrick J Mahaffy,
  See Remarks
• Richard A. Fair,
  Director
• Robert Azelby,
  Director
• Paul Edward Gross,
  See Remarks
• Erle T Mast,
  Executive VP and CFO
• Enterprise Associates 13 Lp...,
  
• Harry R Weller,
  10% owner
• John C Reed,
  Director
• Patrick J Kerins,
  10% owner
• Kathleen K Schoemaker,
  10% owner
• C Richard Kramlich,
  10% owner
• Parters Vii L Pblair James ...,
  
• Peter J Barris,
  10% owner
• Brian H Dovey,
  10% owner
• Steven L. Hoerter,
  SEE REMARKS
• Jesse I Treu,
  10% owner
• Ravi Viswanathan,
  10% owner
• Partners 13, Limited Partne...,
  
• Vii Associates Lp Dp,
  10% owner
• Venture Capital Iv, L.P.Ver...,
  
• David M Mott,
  10% owner
• Scott D Sandell,
  10% owner
• Brian K Halak,
  10% owner
• Nicole Vitullo,
  10% owner
• Vii Associates Lpblair Jame...,
  
• Krishna Kittu Kolluri,
  10% owner
• Ryan D Drant,
  10% owner
• Parters Vii L P Domain,
  10% owner
• Forest Baskett,
  10% owner
• Enterprise Associates 13 Lp...,
  10% owner
• James C Blair,
  Director
• Thomas C. Harding,
  See Remarks